S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
Ruptured oil pipeline off California approved for repairs
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
US shift away from coal hits tribal community in New Mexico
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
Ruptured oil pipeline off California approved for repairs
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
US shift away from coal hits tribal community in New Mexico
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
Ruptured oil pipeline off California approved for repairs
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
US shift away from coal hits tribal community in New Mexico
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
Ruptured oil pipeline off California approved for repairs
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
US shift away from coal hits tribal community in New Mexico
NASDAQ:PBLA

Panbela Therapeutics - PBLA Earnings Date, Estimates & Call Transcripts

$0.27
-0.09 (-24.98%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.25
$0.30
50-Day Range
$0.24
$1.40
52-Week Range
$0.20
$2.40
Volume
1.81 million shs
Average Volume
1.72 million shs
Market Capitalization
$5.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Earnings Summary

Upcoming
Earnings Date
Nov. 9Estimated
Actual EPS
(Aug. 15)
-$1.51 Missed By -$1.29
Consensus EPS
(Aug. 15)
-$0.22
Last Year's Q3 EPS
(8/11/2021)
-$0.22
Skip Charts & View Estimated and Actual Earnings Data

PBLA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PBLA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Panbela Therapeutics Analyst Forecasts

Current Year EPS Consensus Estimate: $-0.84 EPS
Next Year EPS Consensus Estimate: $-0.77 EPS

PBLA Earnings Date and Information

Panbela Therapeutics last issued its earnings results on August 15th, 2022. The reported ($1.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $1.29. Panbela Therapeutics has generated ($2.20) earnings per share over the last year (($2.20) diluted earnings per share). Earnings for Panbela Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.77) per share. Panbela Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 9th, 2022 based off prior year's report dates.

Panbela Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/9/2022
(Estimated)
        
8/15/2022Q2 2022($0.22)($1.51)($1.29)($1.51)
5/12/2022Q1 2022($0.26)($0.27)($0.01)($0.27)    
3/24/2022Q4 2021($0.19)($0.26)($0.07)($0.26)    
11/10/20219/30/2021($0.27)($0.16)+$0.11($0.16)    
8/11/20216/30/2021($0.23)($0.22)+$0.01($0.22)    
5/12/20213/31/2021($0.11)($0.23)($0.12)($0.23)  
3/24/2021Q4($0.1650)($0.09)+$0.0750($0.09)  
11/12/2020Q3 2020($0.21)($0.21)($0.21)












Panbela Therapeutics Earnings - Frequently Asked Questions

When is Panbela Therapeutics's earnings date?

Panbela Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 9th, 2022 based off last year's report dates. Learn more on PBLA's earnings history.

Did Panbela Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Panbela Therapeutics (NASDAQ:PBLA) missed the analysts' consensus estimate of ($0.22) by $1.29 with a reported earnings per share (EPS) of ($1.51). Learn more on analysts' earnings estimate vs. PBLA's actual earnings.

How much profit does Panbela Therapeutics generate each year?

Panbela Therapeutics (NASDAQ:PBLA) has a recorded net income of -$10.14 million. PBLA has generated -$2.20 earnings per share over the last four quarters.

What is Panbela Therapeutics's EPS forecast for next year?

Panbela Therapeutics's earnings are expected to grow from ($0.84) per share to ($0.77) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:PBLA) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.